At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy
In Brief
A clinical study evaluating Neoadjuvant chemradiotherapy and Minimally invasive esophagectomy for Time. Completed, enrolled 303 participants across 1 site.
Detailed Summary
The optimal interval between neoadjuvant chemradiotherapy and esophagectomy is still a question that needs to be explored for patients with esophageal squamous cell carcinoma. In this study, based on previous studies, the investigators divided patients into two groups with a cutoff value of 50 days. By comparing the overall survival and disease-free survival of the entire population and non PCR population, the investigators ultimately obtained the optimal surgical timing suitable for clinical use
Study Details
Timeline
Interventions
Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage
The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes